Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study

Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing

Read more at prnewswire.com